Drugs / Iparomlimab and Toripalimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07619235 | Jun 2026 → Jul 2028 expected | biliary tract cancer | Xianglin Yuan | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Toripalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619235 ↗ |